Navigating from Cellular Phenotypic Screen to Clinical Candidate: Selective Targeting of the NLRP3 Inflammasome
Rosalie Matico,Karolien Grauwen, Dhruv Chauhan,Xiaodi Yu, Irini Abdiaj,Suraj Adhikary, Ine Adriaensen,Garcia Molina Aranzazu, Jesus Alcazar, Michela Bassi, Ellen Brisse, Santiago Canellas, Shubhra Chaudhuri,Francisca Delgado, Alejandro Dieguez-Vazquez, Marc Du Jardin, Victoria Eastham,Michael Finley, Tom Jacobs, Ken Keustermans, Robert Kuhn, Josep Llaveria, Jos Leenaerts,Maria Lourdes Linares, Maria Luz Martin, Rosa Martin-Perez, Carlos Martinez, Robyn Miller, Frances M. Munoz, Michael E. Muratore, Amber Nooyens,Laura Perez-Benito, Mathieu Perrier,Beth Pietrak, Jef Serre,Sujata Sharma,Marijke Somers,Javier Suarez,Gary Tresadern,Andres A. Trabanco, Dries van den Bulck,Michiel Van Gool,Filip Van Hauwermeiren, Teena Varghese,Juan Antonio Vega, Sameh A. Youssef, Matthew J. Edwards,Daniel Oehlrich,Nina Van Opdenbosch EMBO molecular medicine（2024）
Key words
Novel Inhibitor,NLRP3,IL-1 beta,Inflammasome,Clinical Candidate
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper